ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men

ZIM Laboratories Limited has announced that the Therapeutic Goods Administration (TGA), Australia has granted Marketing Authorization (MA) for its Urology product “Tamsulosin Hydrochloride and Dutasteride Capsules” through its Australian subsidiary, ZIMTAS. 

This approval marks ZIM’s second Marketing Authorization in Australia and is an important milestone in the company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies. 

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men. The fixed-dose combination (FDC) formulation improves patient compliance by combining two essential medications into a single daily dose, offering both rapid symptom relief and long-term disease modification. 

This achievement aligns with ZIM’s strategy to leverage its development and manufacturing expertise to build a robust pipeline of differentiated generics for global markets.